|1.||Rosina, F: 1 article (04/2002)|
|2.||Smedile, A: 1 article (04/2002)|
|3.||Mangia, A: 1 article (04/2002)|
|4.||Rizzetto, M: 1 article (04/2002)|
|5.||Andriulli, A: 1 article (04/2002)|
|6.||Martinotti, R: 1 article (04/2002)|
|7.||Borghesio, E: 1 article (04/2002)|
|8.||Conoscitore, P: 1 article (04/2002)|
|1.||Chronic Hepatitis D
04/01/2002 - "To evaluate tolerability and efficacy of thymic humoral factor-gamma 2 in chronic hepatitis D. "
04/01/2002 - "Intramuscular thymic humoral factor-gamma 2, 40 microg, was given for 15 consecutive days and twice weekly for 22 additional weeks to adult patients with chronic hepatitis D virus hepatitis. "
04/01/2002 - "Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study."
04/01/2002 - "At the doses given, thymic humoral factor-gamma 2 has been of limited efficacy A possible role of thymic humoral factor-gamma 2 in the treatment of chronic hepatitis D requires further dose-finding studies and/or combination with other antivirals."
12/01/1996 - "Treatment of murine cytomegalovirus salivary-gland infection by combined therapy with ganciclovir and thymic humoral factor gamma 2."
04/01/2002 - "Thymic humoral factor-gamma 2 is a thymus-derived synthetic octapeptide, shown to be effective in chronic hepatitis B virus infection; as the latter is needed to support hepatitis D virus, thymic humoral factor-gamma 2 may have a therapeutic role in hepatitis D. "
|3.||Chronic Hepatitis B
05/01/1996 - "In mice bearing immunogenic tumors, adding thymic humoral factor-gamma 2 (THF-gamma 2)1 immunotherapy as an adjunct to anticancer chemotherapeutic regimens not only potentiates the antitumor activity of each drug but also repairs tumor/chemotherapy-induced damage to T-cell populations and functions. "
05/01/1996 - "Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy."
09/01/1996 - "The goal of the present study was to determine whether intranasal thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy, after a single dose of chemotherapy, could inhibit the development of lung metastases, restore immunocompetence, and increase survival in syngeneic C57BL/6 mice bearing highly metastatic Lewis lung carcinoma (D122) solid footpad tumors. "
03/01/1999 - "Immunotherapy with the immunomodulating thymic humoral factor-gamma 2 (THF-gamma 2) octapeptide, combined with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy, will be used for enhancing host immune response to arrest pulmonary metastases of a B16-F10.9 melanoma tumor. "
|1.||Antiviral Agents (Antivirals)
|2.||Drug Therapy (Chemotherapy)